Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics, Inc. (RAPT) Accumulated Expenses (2020 - 2024)

RAPT Therapeutics' Accumulated Expenses history spans 5 years, with the latest figure at $6.4 million for Q3 2024.

  • For Q3 2024, Accumulated Expenses fell 19.16% year-over-year to $6.4 million; the TTM value through Sep 2024 reached $6.4 million, down 19.16%, while the annual FY2023 figure was $7.3 million, 109.65% up from the prior year.
  • Accumulated Expenses for Q3 2024 was $6.4 million at RAPT Therapeutics, down from $9.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $11.8 million in Q1 2024 and bottomed at $2.1 million in Q2 2020.
  • The 5-year median for Accumulated Expenses is $5.1 million (2021), against an average of $5.8 million.
  • The largest annual shift saw Accumulated Expenses tumbled 48.03% in 2022 before it surged 338.66% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $3.0 million in 2020, then skyrocketed by 113.21% to $6.3 million in 2021, then tumbled by 45.1% to $3.5 million in 2022, then soared by 109.65% to $7.3 million in 2023, then fell by 12.13% to $6.4 million in 2024.
  • Per Business Quant, the three most recent readings for RAPT's Accumulated Expenses are $6.4 million (Q3 2024), $9.5 million (Q2 2024), and $11.8 million (Q1 2024).